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Abstract
Background: Approximately 4 million of people are co-infected with HIV and Hepatitis B virus (HBV). In resource-limited
settings, the majority of HIV-infected patients initiate first-line highly active antiretroviral therapy containing lamivudine
(3TC-containing-HAART) and long-term virological response of HBV to lamivudine-containing HAART in co-infected patients
is not well known.
Methodology/Principal Finding: HIV-HBV co-infected patients enrolled in the PHPT cohort (ClinicalTrials.gov NCT00433030)
and initiating a 3TC-containing-HAART regimen were included. HBV-DNA, HIV-RNA, CD4+ T-cell counts and alanine
transaminase were measured at baseline, 3 months, 12 months and then every 6 months up to 5 years. Kaplan-Meier
analysis was used to estimate the cumulative rates of patients who achieved and maintained HBV-DNA suppression. Of 30
co-infected patients, 19 were positive for HBe antigen (HBeAg). At initiation of 3TC-containing-HAART, median HBV DNA
and HIV RNA levels were 7.35 log10 IU/mL and 4.47 log10 copies/mL, respectively. At 12 months, 67% of patients achieved
HBV DNA suppression: 100% of HBeAg-negative patients and 47% of HBeAg-positive. Seventy-three percent of patients had
HIV RNA below 50 copies/mL. The cumulative rates of maintained HBV-DNA suppression among the 23 patients who
achieved HBV-DNA suppression were 91%, 87%, and 80% at 1, 2, and 4 years respectively. Of 17 patients who maintained
HBV-DNA suppression while still on 3TC, 4 (24%) lost HBsAg and 7 of 8 (88%) HBeAg-positive patients lost HBeAg at their
last visit (median duration, 59 months). HBV breakthrough was observed only in HBeAg-positive patients and 6 of 7 patients
presenting HBV breakthrough had the rtM204I/V mutations associated with 3TC resistance along with rtL180M and/or
rtV173L.
Conclusions: All HBeAg-negative patients and 63% of HBeAg-positive HIV-HBV co-infected patients achieved long-term
HBV DNA suppression while on 3TC-containing-HAART. This study provides information useful for the management of co-
infected patients in resource-limited countries where the vast majority of co-infected patients are currently receiving 3TC.
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Introduction
In 2010, the World Health Organization (WHO) estimated that
34 million people were HIV infected worldwide [1]; of whom,
approximately 4 million have chronic hepatitis B virus (HBV)
infection (defined by more than 6 months of hepatitis B surface
antigen or HBsAg in the blood) [2]. These HIV-HBV co-infected
individuals are at risk of accelerated liver disease progression,
aggressive hepatocellular carcinoma and 8-fold increased liver-
related mortality rate [3,4].
Current guidelines for the use of antiretroviral agents in HIV-1-
infected patients [5,6,7], recommend to screen HBsAg in all HIV
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e42184patients prior to initiating antiretroviral treatment (ART), and if
found positive, initiate combination antiretroviral with a tenofovir
disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine
(FTC) backbone. However, since HBsAg testing has not been
available or is too costly in many resource-limited settings, HBV
infection status is unknown for the vast majority of HIV infected
patients who have thus received a standard first line that includes
3TC as part of triple combination antiretroviral therapy.
Lamivudine is a cytidine analogue that inhibits the reverse
transcriptase of both HIV and HBV [8,9,10]. However, its major
drawback is the progressive emergence of resistance mutations at
a rate of 15–20% per year in HBV-HIV-1 co-infected patients in
developed countries [11,12]. New generation nucleos(t)ide analo-
gues with higher resistance barriers have been produced, in
particular TDF for which no resistance mutation has been
detected in chronically HBV infected patients after 3 years of
therapy [13]. However, in resource-limited countries, most of
these new drugs are not available or too expensive. Indeed, the
2008 Asian Pacific Association for the Study of the Liver (APASL),
still recommends 3TC for treatment of HBV mono-infection in
endemic areas [14].
In Thailand, since the national scale-up of ART in 2004 [15],
over 95% of HIV-infected patients have received 3TC as part of
highly active antiretroviral therapy (HAART) [16] and there are
still numerous HIV-HBV co-infected patients on 3TC-containing
HAART regimens for whom the long-term benefit of 3TC on
HBV replication and the incidence of 3TC resistance mutations
are not well known. We report the analysis of virological efficacy of
3TC on HBV replication and emergence of 3TC resistance HBV
variants in HBV-HIV-coinfected patients receiving up to 5 years
of 3TC-containing HAART regimens.
Methods
Patients
Patients were enrolled in the prospective multicenter Program
for HIV Prevention and Treatment (PHPT) cohort (Clinical-
Trials.gov Identifier: NCT00433030) of HIV-infected adults on
antiretroviral therapy in Thailand and provided written informed
consent at entry. This cohort study was approved by the Thai
Ministry of Public Health and ethic committees at Chiangrai
Prachanukroh, Prapokklao, Chonburi, Bhuddasothorn, Somdej
Prapinklao, Nopparat Rajathanee, Bhumibol Adulyadej, Buddha-
chinaraj, Hat Yai, Samutsakorn, Nakhonpathom, Maharaj
Nakornratchasrima, Sanpatong Hospitals. All investigators con-
ducted the study according to the principles expressed in the
Declaration of Helsinki. This sub-study was also approved by the
ethic committee of the Faculty of Associated Medical Sciences,
Chiang Mai University.
At entry, prior to starting HAART, all patients were screened
for HBsAg and anti-HCV antibodies and had CD4+ T-cell count
and plasma HIV RNA load performed. Following HAART
initiation, CD4+ T-cell enumeration and plasma HIV RNA were
measured every 6 months. Patients received a quarterly clinical
biological follow-up and compliance was assessed at each visit by
pill count and self-reporting.
Patients were included in this analysis if 1) HBsAg positive, 2)
receiving HAART regimens which included 3TC (150 mg twice
a day), 3) stored blood samples collected prior to 3TC initiation
(baseline), and on HAART (3-month, 12-month, annual sample
until up to 5 years) were available, and 4) HBV DNA was
detectable at baseline.
HBV Markers and HIV RNA Quantification
HBsAg and HBeAg were tested at baseline using DiaSorin ETI-
MAK-4 and DiaSorin ETI-EBK PLUS (Salluggia, Italy), re-
spectively. HBsAg was tested in patients on 3TC treatment using
the MonoLisaH HBsAg ultra with a sensitivity of 50 pg/mL (Bio-
Rad laboratories, France). HBV viral load was quantified using the
Abbott real-time HBV DNA
TM assay, Rungis, France (lower limit
of detection 1.18 log10 IU/mL). HIV RNA was quantified using
the COBAS Amplicor HIV-1 Monitor Test v.1.5. (Roche
Molecular Systems, Branchburg, NJ) (lower limit of detection:
1.70 log10 copies/mL) and the Abbott real-time HIV RNA
TM
assay, Abbott, (lower limit of detection: 1.6 log10 copies/mL).
HBV Virological Responses
HBV responses to 3TC were categorized according to the
APASL recommendations [14]; HBV DNA suppression was
defined as undetectable level of HBV DNA (the threshold used
was 2.18 log10 IU/mL since some samples were diluted 1:10 due
to insufficient volume); virological breakthrough defined as an
initial decline .2 log10 IU/mL followed by an increase of HBV
DNA .1 log10 IU; and maintained viral suppression defined as
HBV DNA level persistently ,2.18 log10 IU/mL.
HBV DNA Sequencing
All baseline samples as well as any sample with detectable HBV
DNA on 3TC-containing-HAART were tested for HBV resistance
mutation; HBV DNA sequencing was performed as previously
described [17] with slight modification of PCR conditions. First
round PCR conditions consisted of an initial 2 min denaturation
step at 94uC, followed by 40 cycles of 1 min at 94uC for, 1 min at
48uC, and 3 min at 68uC. The second-round PCR included an
initial denaturation step of 2 min at 94uC, followed by 30 cycles of
40 sec at 94uC, 1 min at 55uC, and 3 min at 68uC. The second-
round PCR products were sequenced using the nested pol3M and
pol4M primers and the BigDye Terminator Mix V. 1.1 (Applied
Biosystems, Foster city, CA). Sequences were analyzed using the
Bioedit software (http://www.mbio.ncsu.edu/bioedit) and HBV
genotype was identified by phylogenetic analysis. HBV pol
sequences were analyzed for polymorphisms and mutations known
to be associated with 3TC resistance through comparison with
wild-type reference sequences of similar genotype [18].
Statistical Analyses
Baseline characteristics are reported as percentage with 95%
confidence interval (95%CI) or medians with interquartile ranges
(IQR) and were compared according to HBeAg status using
Fisher’s exact test for categorical variables and Wilcoxon rank-sum
test for continuous variables. Kaplan-Meier analysis was used to
estimate the cumulative rates of achieving serum HBV DNA and,
in those who achieved HBV DNA suppression, the duration of
maintaining such suppression. Duration of HBV DNA suppression
was counted from the date of first viral suppression until the date
of first detectable HBV DNA or, if a patient was lost to follow-up
or switched to a regimen without 3TC, the date of last
undetectable HBV DNA load. Log-rank test was used to compare
the cumulative rates of virological responses between HBeAg-
positive and HBeAg-negative patients. For the analysis of
association between the baseline CD4, HIV RNA, HBV DNA
levels and virological responses to 3TC-containing HAART,
continuous data were dichotomized according to the median
baseline values and analysis was performed using Fisher’s exact or
log-rank tests. Statistical significance was defined as p,0.05. Data
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TM version 10.1 software (Statacorp,
College Station, Texas, USA).
Results
Baseline Characteristics
Of 1,448 HIV infected adults on HAART, 122 (8.4%) tested
HBsAg-positive. Thirty patients met all criteria for this analysis i.e.
receiving 150 mg twice a day (bid) of 3TC as part of HAART,
blood samples collected at baseline and on 3TC-based treatment
and detectable HBV DNA at baseline (Figure 1). Nineteen patients
(63%) were HBeAg-positive. Patients’ baseline characteristics were
not different between HBeAg-positive and -negative patients
(Table 1), except for the median HBV DNA level significantly
higher, as expected, in HBeAg-positive patients and the alanine
transaminase (ALT) level which tended to be higher in HBeAg-
negative patients than in HBeAg-positive patients. Phylogenetic
analysis indicated that 17% of patients were infected with HBV B
genotype and 83% with C genotype (data not shown). None had
HCV infection. Twelve patients (40%) had received previous
antiretroviral treatment but none had been exposed to 3TC except
one for a short period of 1 month. Over the course of 3TC-
containing HAART, 29 of 30 patients had .95% adherence by
pill count and 20 patients self-reported that they always missed #1
dose per week.
Efficacy of 3TC on HBV Replication
After 3 month of HAART, median reduction of HBV DNA
was 3.86 log10 (IQR, 2.56–4.67), and 47% (95%CI, 28–66) of
patients achieved HBV DNA suppression. At 12 months, median
HBV DNA reduction was 4.40 log10 (IQR, 2.89–5.65) IU/mL
and 20 patients (67%; 95%CI, 47–83) of patients achieved HBV
DNA suppression.
The rate of HBV DNA suppression at 12 months was
significantly higher among HBeAg-negative patients than among
HBeAg-positive patients (100% and 47%, respectively; p=0.004;
Table 2 and Figure 2). Kaplan-Meier analysis showed that
HBeAg-negative patients achieved HBV DNA suppression more
rapidly than HBeAg-positive patients (p=0.01). Six patients had
partial HBV virological response and 4 experienced a HBV
breakthrough during the first 12 months; of whom 2 had HBV
DNA suppression at 3 months and 2 never fully suppressed HBV
replication.
Over 5 years of follow-up, 17 of 20 patients who achieved HBV
DNA suppression at 12 months were able to control their HBV
replication until their last medical visit (with a median of
59 months [IQR, 32–60]), 2 had a viral breakthrough and one
had no long-term sample available.
Of 6 patients with partial HBV virological response at
12 months, one patient achieved slower HBV DNA suppression,
at 38 months of treatment, 3 had detectable HBV DNA (i.e. 2.71,
2.84, and 4.76 log10 IU/mL), one had a viral breakthrough at
24 months of treatment, and one switched treatment regimen
(Table S1).
To analyze the relation between baseline HIV RNA load and
HBV virological response to 3TC-containing HAART, patient
baseline HIV RNA levels were dichotomized according to the
median baseline HIV RNA level (4.47 log10 copies/mL). The
baseline HBV DNA levels did not differ between the two baseline
HIV RNA groups (7.19 versus 7.42 log10 IU/mL, p=0.31). At
one year, there was no difference in HBV response (67% versus
67%) by baseline HIV RNA group. Furthermore, there was no
difference in response during 5-years of 3TC-containing HAART
(log-rank p-value =0.26).
The duration of HBV DNA suppression was analyzed for the 23
patients who achieved HBV DNA suppression (i.e. 20 achieved
HBV DNA suppression at 12 months, 2 had a viral breakthrough
Figure 1. Disposition of patients included in this study.
doi:10.1371/journal.pone.0042184.g001
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12 months of treatment). Eighteen (78%) maintained HBV DNA
suppression up to their last visit, 4 (17%) had a HBV
breakthrough, and one changed drug regimen after 15 months
of 3TC treatment (Table S1). The cumulative rates of maintained
HBV DNA suppression were estimated to be 91% (95%CI; 69–
98), 87% (95%CI; 64–95), 80% (95%CI; 55–92) and 80%
(95%CI; 55–92) at 1, 2, 3, and 4 years, respectively (Figure 3).
HBV Serological Evaluations in Patients on 3TC-contained
HAART
Of the 18 patients who maintained long-term HBV DNA
suppression, 17 had a sample available for HBsAg testing. Four
patients (24%) lost HBsAg at their last visit; one was HBeAg
positive and three were HBeAg negative when initiating of 3TC-
based HAART. Among the 8 HBeAg positive patients, 7 lost
HBeAg at their last visit.
3TC Resistance-associated Mutations
There was no mutation associated with resistance to 3TC
observed in all 30 patients before initiation of 3TC-containing-
HAART. The 5-year cumulative rate of 3TC resistance was 20%
(6/30); all of which was found in HBeAg positive patients. The
mutations were found in 6 of 7 patients with viral breakthrough.
Early viral breakthrough (within 1 year of therapy) occurred
between 4 and 12 months in 4 patients. One patients had the
HBV mutation ntG741A (G to A nucleotide at position 741),
resulting in the known 3TC-associated resistance mutation
rtM204I. This mutation led to the concomitant substitution of
tryptophan to stop codon at position 196 (sW196stop) in the
surface protein. The ntT843G mutation of unknown significance
was also observed and resulted in the change from asparagine to
lysine in the reverse transcriptase protein (rtN238K). In the 3 other
patients, the viral breakthrough was not associated with the
detection of HBV resistance mutations; however the M204V
mutation was detected later during the follow-up in 2 patients, (i)
at 42 months, along the compensatory resistance mutations
rtV173L+L180M in one patient, and (ii) at 78 months with
rtL180M mutation in one patient. No long-term HBV sequence
was available for the third patient due to subsequent switch to non-
3TC including regimen.
Late HBV breakthrough occurred in 3 patients and was
associated with the emergence of 3TC-resistance mutations:
rtV173L+L180M+M204I, rtL180M+M204V and
rtL180M+M204I. Four patients never achieved undetectable
Table 1. Baseline demographic and clinical characteristics of the study population.
Baseline characteristics Overall HBeAg positive (N=19) HBeAg negative (N=11) p-value
a
n Value n Value n Value
Age (year) [median (IQR)] 30 31 (27–34) 19 29 (27–33) 11 33 (27–35) 0.59
Female [n (%)] 30 24 (80) 19 17 (89) 11 7 (64) 0.16
Treatment-experienced [n (%)] 30 12 (40) 19 7 (37) 11 5 (45) 0.71
CD4+ T-cell count (x10
6/L) [median (IQR)] 30 100 (38–178) 19 110 (38–188) 11 48 (33–178) 0.78
HIV RNA (log10copies/mL) [median (IQR)] 30 4.47 (4.09–5.27) 19 4.46 (4.06–5.25) 11 5.25 (4.25–5.50) 0.29
Alanine transaminase (IU/L) [median (IQR)] 30 30 (20–39) 19 27 (17–36) 11 44 (21–121) 0.06
HBV DNA (log10IU/mL) [median (IQR)] 30 7.35 (5.55–8.07) 19 7.92 (7.34–8.31) 11 3.76 (3.28–6.67) ,0.001
HBV Genotype B : C [n (%)] 30 5:25 (17:83) 19 4:15 (21:79) 11 1:10 (9:91) 0.63
aFisher’s exact test or Wilcoxon rank-sum test were used.
doi:10.1371/journal.pone.0042184.t001
Table 2. HBV and HIV response to 3TC in HIV-1/HBV co-infected patients during 12 months of treatment.
Overall (N=30) HBeAg positive (N=19) HBeAg negative (N=11) p-value
a
n
%[95%CI] or median
[IQR] n
%[95%CI] or median
[IQR] n
%[95%CI] or median
[IQR]
HBV DNA suppression
b
at 3 months 14 47 [28–66] 6 32 [13–57] 8 73 [39–94] 0.06
at 12 months 20 67 [47–83] 9 47 [24–71] 11 100 [72–100] 0.004
HIV load #50 cp/mL
at 3 months 22 73 [54–88] 13 68 [43–87] 9 82 [48–98] 0.67
at 12 months 22 73 [54–88] 14 74 [49–91] 8 73 [39–94] 1.00
HIV RNA reduction
at 3 months (log10 cp/mL) 2.92 [2.54–3.53] 2.93 [2.14–3.48] 2.91 [2.54–4.08] 0.53
at 12 months (log10 cp/mL) 2.92 [1.52–3.45] 2.93 [1.52–3.32] 2.91 [1.17–4.08] 0.78
aFisher’s exact test or Wilcoxon rank-sum test were used.
bHBV DNA suppression was defined as serum HBV DNA level equal or below 150 or 2.18 log10 IU/mL.
doi:10.1371/journal.pone.0042184.t002
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switched to non-3TC regimen or recieved add-on TDF.
Efficacy of HAART on HIV Replication, CD4 Cell Count and
Alanine Transaminase Levels
At 3-month, the median reduction of HIV RNA was 2.92 log10
(IQR, 2.54–3.53) and 73% patients achieved undetectable HIV
RNA load (,1.7 log10 or 50 copies/mL). At 12-month, the
median HIV RNA reduction was 2.92 log10 (IQR, 1.52–3.45)
copies/mL and 73% patients achieved undetectable HIV RNA
load. Reduction of HIV RNA levels and proportions of undetect-
able HIV RNA were similar irrespective of baseline HBV DNA
level and HBeAg status (Table 2). Six patients had HIV RNA load
above 500 copies/mL and all presented the M184I/V mutations
associated with HIV resistance to 3TC. Median CD4+ T-cell
counts increased from 100 (IQR: 38–178)610
6 cells/L at baseline
to 247 (IQR: 197–374) at 12-month and 472 x10
6 cells/L at
5 years of treatment, respectively. Median ALT was 30 (IQR: 20–
39) IU/L and decreased but not significantly to 21 IU/L (IQR:
16–29) at 5 years of 3TC treatment. Kinetics of CD4+ T-cell
counts and serum ALT levels in HIV-HBV co-infected patients
after initiation of 3TC-containing HAART are showed in Figure 4,
according to their HBeAg status. Patients with baseline CD4 T-
cell counts above the median (100610
6 cells/L) had similar rates
of undetectable levels of both HBV DNA and HIV RNA over
5 years of 3TC-containing HAART as those with CD4 T-cell
counts below the median (log-rank p-values: 0.42 for HBV and
0.41 for HIV). Also, over 5-years of 3TC-containing HAART,
there was no difference in increase of absolute CD4+ T-cells count
among HBV virological responders and non-responders.
Discussion
We analyzed the long-term HBV and HIV virological response
in a group of 30 HIV-HBV co-infected patients, 63% HBeAg-
positive, who received 3TC, as part of HAART regimen. After
12 months of 3TC-containing-HAART, the rate of HBV DNA
suppression in our study was 67%, compared to the 40% reported
in the international collaborative (CAESAR) study conducted in
Canada, Australia, Europe and Africa [8] despite higher median
HBV DNA level prior to 3TC initiation, 7.35 vs. 6.87 log10 IU/
mL. A recent study conducted in Kenya [19] reported that 89%
(17 of 19) of HIV-HBV co-infected patients achieved HBV DNA
suppression (,100 IU/mL) after 18 months of 3TC treatment.
The rate of HBV DNA suppression among HBeAg negative
patients was 94% (17 of 18) similar to the 100% rate observed in
Figure 2. HBV DNA and HIV RNA load in HIV-HBV co-infected patients after initiation of 3TC-containing-HAART. Dotted line indicates
the lower limit of detection for HBV DNA (2.18 log10 IU/mL).
doi:10.1371/journal.pone.0042184.g002
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among 57 HIV-HBV co-infected patients in South Africa [20]
showed that HBV DNA suppression rate slight increased from 7%
at baseline to 34% at 3 months of 3TC treatment and remained
stable until 12 months. In the PHIDISA II study, the baseline
HBV DNA level was 7.00 log10 IU/mL and similar to the level in
our study. Furthermore, we found no relation between the baseline
HIV RNA level and HBV response to 3TC-containing HAART
or between the baseline HBV DNA level and HIV response to
3TC-containing HAART. Baseline CD4 count was not associated
with either HBV or HIV virological response. In addition, over 5-
years of 3TC-containing HAART, increases of absolute CD4+ T-
cells count were not different among HBV virological responders
and non-responders.
Among the 23 patients who had achieved HBV DNA
suppression, 18 (78%) maintained HBV DNA suppression over
a median of 51 months. This rate is much higher than the 9%
reported by Benhamou et al, in HIV-HBV co-infected patients
after 4 years of treatment with the same dosing of 3TC [11]. Of
interest the threshold used to define HBV DNA suppression was
4.03 log10 IU/mL while it was 2.18 log10 IU/mL in our study.
The higher response rate in our study may be due to a better
compliance of patients to their treatment as evidenced by 73% of
patients achieving HIV RNA below 50 copies/mL at 12 months
and most of patients had undetectable HIV RNA, except some
with high replication of drug-resistant strains. Another possibility
could be that the HBV genotypes B and C are more sensitive to
3TC than genotypes A and D, which require confirmation with
in vitro experiments. HBV DNA suppression was maintained in all
HBeAg-negative patients. The higher rate of response to 3TC
treatment and duration of HBV DNA suppression among HBeAg-
negative patients suggest that, in resource-limited countries,
HBeAg testing may be a valuable marker to predict the virological
response to 3TC and could be considered when initiating in HIV-
HBV co-infected patients the first-line HAART which usually
includes 3TC. Other studies conducted among patients with
chronic HBV infection in Japan and Brazil showed that HBeAg-
negative patients had better HBV response to 3TC [21,22].
HBeAg seroconversion and HBsAg loss are usually associated
with favorable clinical outcome. Twenty-four percent (4/17) of
patients lost HBsAg and 88% (7/8) of HBeAg-positive patients lost
HBeAg at their last visit (median duration of 59 months).
Although our study had a limited number of patients, our results
are consistent with those reported in a recent study conducted in
Taiwan among HBV-HIV infected patients receiving 3TC-
containing HAART (median duration of 34 months), 6% (6/
108) of HBsAg loss and 46% (21/46) of HBeAg seroconversion
[23].
One major limitation of treating HBV with 3TC monotherapy
is the rapid emergence of resistance mutations. In HBV-HIV-1 co-
infected patients, resistance mutations to 3TC have been shown to
occur at a rate of 15–20% per year [11,24]. In our study, the
incidence of 3TC resistance mutations detected during the first
year of therapy was 3% (1of 30) which is comparable to the 7% (2
of 27) in a study conducted in Kenya (p=0.60) [19]. Over the
5 years of follow-up, 6 of 7 patients presenting HBV breakthrough
Figure 3. Kaplan-Meier curve of time to loss of HBV DNA suppression in 23 HIV-HBV co-infected patients who had achieved HBV
DNA suppression during the course of 3TC-containing-HAART.
doi:10.1371/journal.pone.0042184.g003
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M204V mutations associated with 3TC resistance along with
rtL180M and/or rtV173L. Despite good compliance to treatment,
as evidenced by the HIV RNA suppression, some patients had
experienced HBV breakthrough without any mutations within the
pol gene. This may be due to the emergence of mutations outside
the rt domain or other mechanisms yet to identified.
A nucleotide analogue, TDF, has been shown to be active
against both wild-type and 3TC resistant HBV [25,26]. It has
recently been available in Thailand at the price of 38 USD per
month, which exceeded that of the current standard first line
HAART (zidovudine/stavudine, 3TC and nevirapine), 30 USD
per month [27,28]. Although the Thai national [29], US [6] and
WHO guidelines [30], have recommended the use of TDF+3TC
or TDF+FTC as the backbone of HAART combination to treat
HIV-HBV co-infected patients, this combination may not be
provided to all HIV-HBV co-infected patients. Indeed, identifying
HBV co-infected patients still poses a problem as shown in the
study of Sungkanuparph et al where about 42% of Thai HIV-1
infected patients on ART had not been assessed for HBV co-
infection [31].
In conclusion, our study shows that all HBeAg negative patients
and a significant number of HBeAg positive HIV-HBV co-infected
patients can achieve long-term HBV DNA and HIV suppression
on 3TC containing HAART. The results of this study provide
further information which may be useful for the management of
HIV-HBV co-infected patients in resource-limited countries where
the vast majority of HIV-HBV co-infected patients are currently
receiving 3TC.
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